Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  3  4  Next»
    Study title: Prophylaxis of infections Adherence of bacterial microorganisms to epithelial cells and blocking by secretory antibodies after oral administration of Luivac; Therapiewoche Pädiatrie 9, 421-423, Volume 7/8, July/August 1996Prophylaxis of infections Adherence of bacterial microorganisms to epithelial cells and blocking by secretory antibodies after oral administration of Luivac; Therapiewoche Pädiatrie 9, 421-423, Volume 7/8, July/August 1996
    Active substance: Bacterial lysate
    Study summary document link (including results):
    View full study record
    Document reference: 41826
    Study title: Report on the immunohistological analysis of anti-Luivac antibody producing cells in tonsils of patients from the Hint Study
    Active substance: Bacterial lysate
    Study summary document link (including results):
    View full study record
    Document reference: 41827
    Study title: Prophylaxis of atopic and allergic manifestations and activation or modulation of endogenic resistance by Pro-Symbioflor in infants and toddlers of atopicly affected parents
    Active substance: Bacterial lysate with MGE-score of at least 8 consisting of - inactivated cells and cell debris of 1.5–4.5 x 107 Enterococcus faecalis (DSM 16440) - inactivated cells and cell debris of 1.5–4.5 x 107 Escherichia coli (DSM 17252)
    Study summary document link (including results):
    View full study record
    Document reference: 41337
    Study title: Efficacy and safety of Symbioflor 1 in children and adolescents with chronic recurrent sinusitis (non-interventional trial)
    Active substance: Bacterial culture with MGE-score of at least 6 consisting of 1.5–4.5 x 107 cells capable and not capable of reproduction and cell debris of Enterococcus faecalis (DSM 16440)
    Study summary document link (including results):
    View full study record
    Document reference: 21213
    Study title: Efficacy and safety of Symbioflor 2 in children with irritable bowel syndrome (non-interventional trial); Martens -Probiotic treatment of irritable bowel syndrome in children -Symbioflor2en 2010
    Active substance: Bacterial culture with MGE-score of at least 8 consisting of 1.5–4.5 x 107 cells capable and not capable of reproduction and cell debris of Escherichia coli (DSM 17252)
    Study summary document link (including results):
    View full study record
    Document reference: 41389
    Study title: Prophylaxis of infections Adherence of bacterial microorganisms to epithelial cells and blocking by secretory antibodies after oral administration of Luivac; Therapiewoche Pädiatrie 9, 421-423, Volume 7/8, July/August 1996
    Active substance: BACAMPICILLIN
    Study summary document link (including results):
    View full study record
    Document reference: 22062
    Study title: Report on the immunohistological analysis of anti-Luivac antibody producing cells in tonsils of patients from the Hint Study
    Active substance: BACAMPICILLIN
    Study summary document link (including results):
    View full study record
    Document reference: 22063
    Study title: Uptake of Lipiodol(trademark) -cytotoxic conjugates by hepatoblastoma cells.
    Active substance: Ethyl esters of iodized fatty acids of poppy seed oil
    Study summary document link (including results):
    View full study record
    Document reference: 39918
    Study title: Anderson, R. A., Corr, T. R., Hewitt, L. A., et al. A phase II study of filgrastim-mobilized peripheral blood progenitor cells (PBPC) infusion support for relapsed pediatric solid tumors being treated with ifosfamide, carboplatin and etoposide (ICE) Blood 90(10 SUPPL: 15, 1997.Anderson, R. A., Corr, T. R., Hewitt, L. A., et al. A phase II study of filgrastim-mobilized peripheral blood progenitor cells (PBPC) infusion support for relapsed pediatric solid tumors being treated with ifosfamide, carboplatin and etoposide (ICE) Blood 90(10 SUPPL: 15, 1997.
    Active substance: FILGASTRIM
    Study summary document link (including results):
    View full study record
    Document reference: 27282
    Study title: Effects of SL 87.0495-23, diltiazem and elgodipine on hypoxia-induced lactate deshydrogenase release from cultured cells neonatal rat cardiomyocytes - Briand V.Galzin A.M - 02/12/92
    Active substance: DILTIAZEM
    Study summary document link (including results):
    View full study record
    Document reference: 26102
    Study title: Cetirizin effects on children with atopic dermatitis. correlation among the eosinophil cationic protein (ecp), il2r soluble (cd25), cd23 (b cells) and clinical score.
    Active substance: CETIRIZINE
    Study summary document link (including results):
    View full study record
    Document reference: 23689
    Study title: Cetirizine reduces cytokines and inflammatory cells in children with perennial allergic rhinitis.
    Active substance: CETIRIZINE
    Study summary document link (including results):
    View full study record
    Document reference: 23686
    Study title: Hourly monitoring of circulating CD34+ cells to optimize timing of autologous apheresis in pediatric patients
    Active substance: DACTINOMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 25362
    Study title: Effects of different magnitudes of cyclic stretch on Na+-K+-ATPase in skeletal muscle cells in vitro.
    Active substance: DACTINOMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 25340
    Study title: Assessment of safety and immunogenicity of Merieux Vero OPV in France (ASTER ref. JT1903/1) (1987)
    Active substance: Trivalent Oral Poliomyelitis Vaccine (Vero cells)
    Study summary document link (including results):
    View full study record
    Document reference: 41294
    Study title: Assessment of safety and immunogenicity of Merieux Vero OPV in Morocco (ASTER ref. JT1903/2) (1987)
    Active substance: Trivalent Oral Poliomyelitis Vaccine (Vero cells)
    Study summary document link (including results):
    View full study record
    Document reference: 41296
    Study title: Assessment of safety and immunogenicity of Merieux Vero OPV in Morocco (ASTER ref. JT1903/3) (1988)
    Active substance: Trivalent Oral Poliomyelitis Vaccine (Vero cells)
    Study summary document link (including results):
    View full study record
    Document reference: 41295
    Study title: Assessment of the immunogenicity and safety of three different formulation F3, F3+alum and F3bis of a pneumococcal polysaccharide conjugate vaccine in healthy Chilean infants (PNF 30298) ( 2000)
    Active substance: Trivalent Oral Poliomyelitis Vaccine (Vero cells)
    Study summary document link (including results):
    View full study record
    Document reference: 41297
    Study title: Immunogenicity and response to polysaccharide challenge following different schedules of a Neisseria meningitidis A/C diphtheria conjugate vaccine administered to infants in Niamey, Niger (MAK02297) (1997)
    Active substance: Trivalent Oral Poliomyelitis Vaccine (Vero cells)
    Study summary document link (including results):
    View full study record
    Document reference: 41298
    Study title: Immunogenicity and safety of an inactivated Hepatitis A vaccine (80 AgU) after simultaneous administration with either Tetract-Hib+OPV or DtacP-IPC//Act-Hib vaccine in 16 to 19 month old toddlers (HAF29393) (1999)
    Active substance: Trivalent Oral Poliomyelitis Vaccine (Vero cells)
    Study summary document link (including results):
    View full study record
    Document reference: 41299
    1  2  3  4  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 03:56:44 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA